Recombinant adeno-associated virus (rAAV) vectors possess a number of properties that may make them suitable for clinical gene therapy, including being based upon a virus for which there is no known pathology and a natural propensity to persist in human cells. Wild-type adeno-associated viruses (AAVs) are now known to be very diverse and ubiquitous in humans and nonhuman primates, which adds to the degree of confidence one may place in the natural history of AAV, namely that it has never been associated with any human tumors or other acute pathology, other than sporadic reports of having been isolated from spontaneously aborted fetuses. On the basis of this understanding of AAV biology and a wide range of preclinical studies in mice, rabbits, dogs and nonhuman primates, a growing number of clinical trials have been undertaken with this class of vectors. Altogether, over 40 clinical trials have now been approved. Although all previous trials were undertaken using AAV serotype 2 vectors, at least two current trials utilize AAV2 vector genomes cross-packaged or pseudotyped into AAV1 capsids, which appear to mediate more efficient gene delivery to muscle. The explosion of capsid isolates available for use as vectors to over 120 has now provided the potential to broaden the application of AAV-based gene therapy to other cell types.
Gene therapy for cystic fibrosis
The earliest uses of recombinant adeno-associated virus (rAAV) for clinical gene therapy were for monogenic disorders. The initial trial involved airway delivery (nasal, endobronchial, sinus and aerosol inhalation) in cystic fibrosis patients with mild lung disease. 1 The second set of trials and the first published involved intramuscular (IM) and hepatic delivery rAAV2-Factor IX vectors in patients with hemophilia B. 2 In the case of the rAAV2-cystic fibrosis transmembrane conductance regulator (rAAV2-CFTR) program, preclinical data in New Zealand white rabbits showed 6-month persistence of CFTR mRNA after endobronchial instillation. 3 Two additional studies were performed in rhesus macaques; the first indicated that rAAV2-CFTR delivery was relatively safe, although adeno-associated virus (AAV)2 vector genomes were found in the blood for a period of time after vector delivery. 4 The second study convincingly demonstrated that rAAV2-CFTR vector was not mobilized after concomitant wild-type AAV2 and adenovirus infection. 5, 6 On the basis of these studies, a phase I clinical trial was performed involving sequential intranasal and endobronchial instillation of rAAV2-CFTR in adult cystic fibrosis patients. 1, 7 This initial study demonstrated safety over a 7-log fold dose range. A subsequently published analysis of primary cell culture samples taken from these same patients after vector delivery indicated a good correlation between the presence of vector DNA sequences, mRNA expression and electrophysiologic correction of cAMP-activated chloride transport. 8 Later studies of delivery to the maxillary sinuses and to the lower respiratory tract by aerosol delivery both showed DNA transfer and trends toward positive biological effects for the first 60 days after vector delivery. [9] [10] [11] [12] [13] However, in each of these trials, patients developed antibody responses to AAV2 capsids. Given the limited duration of the biological effects and the immunologic barriers to repeated dosing, clinical studies with this particular vector were concluded after phase IIb studies, with a total of over 120 subjects treated without a single vector-related significant adverse effect (Table 1) .
Gene therapy for hemophilia B
The results of studies of rAAV2-FIX vectors were similar in a number of ways. A strong platform of preclinical trials, including both small animal safety studies, biodistribution studies in rabbits and efficacy studies in dogs led to the initiation of two phase I clinical trials. [14] [15] [16] [17] The first trial of IM injection of rAAV2-FIX dramatically demonstrated transient expression of FIX and partial correction of bleeding time. 2, 18 These effects were transient, and once again anti-AAV2 antibodies were generated in these patients, indicating that repeated dosing was unlikely to be effective. These findings led to a second study involving intrahepatic delivery of the vector, which also indicated evidence of in vivo gene expression and correction of bleeding time to a significantly greater degree than in the IM trial. 19 The second study led to two very important findings, the potential of vector distribution to the semen, which was transient, and the development of cell-mediated immune responses to AAV2 capsid. The latter finding was associated with transient elevation of transaminases without clinically significant liver dysfunction. There was also a correlation between developing these cellmediated immune responses and eliminating transgene expression from the patient's hepatocytes. This association did not prove causality, but was suggestive of a link between these two findings.
Taken together, these two sets of studies provide a remarkably consistent picture of rAAV2-based gene transfer in humans. The key differentiating factor reinforced the natural history-based assumption that rAAV2-mediated gene delivery would be safe in humans. However, overall vector expression was low and transient in both trials, and the development of immune responses to the AAV2 capsid appeared likely to hinder effective repeated delivery. Following these trials, one major research effort was directed to modulating or avoiding these immune responses and another major effort was focused on strategies for increasing the efficiency of gene transfer. The subsequent clinical trial programs have generally addressed this, in some cases by targeting cells and tissues for which rAAV2 has a greater efficiency of gene transfer (such as central nervous system (CNS), retina or joint capsule) or most recently by switching to alternative serotypes that are intrinsically more efficient for gene transfer.
More recent rAAV2 clinical trials

Ocular gene therapy
A number of rAAV2 trials have been undertaken within the past several years that target CNS or retina (Table 1) . Retinal diseases comprise a significant number of genetic defects. One of these is Leber congenital amaurosis with about 15% of the cases being caused by mutation in the RPE65 gene. Leber congenital amaurosis an autosomal recessive disorder progressively leading to blindness by age 10 years, is due to the crucial role of RPE65 in the retinoid cycle. Preclinical studies in canine models of this disease showed that subretinal delivery of an AAV2 vector expressing the functional RPE65 gene halted retinal degeneration and restored vision. [20] [21] [22] Subsequently, nonhuman primate studies delivering single intraocular injections of rAAV2-RPE65 did not identify any systemic toxicity and only minor signs of local inflammation that resolved within a week after delivery. Furthermore, morphometric analysis showed that there Clinical gene therapy using rAAV vectors C Mueller and TR Flotte was no photoreceptor abnormalities associated with AAV delivery. 23, 24 These results provided the data necessary for preparation of a phase I dosing clinical trial for Leber congenital amaurosis to assess the safety and tolerability of retinal administration of AAV. This trial is currently active with three patients having received the rAAV2-RPE65 vector and no reported adverse events to date (personal communication).
Gene therapy for the central nervous system
The first use of rAAV to mediate gene delivery to the CNS was developed for a therapeutic approach to Canavan disease. This monogenic autosomal recessive disease is a pediatric neurodegenerative disorder stemming from the lack or mutation of the aspartoacylase (ASPA) enzyme. Nonfunctional enzyme leads to an accumulation of its substrate N-acetylaspartate, which prevents normal myelination and results in spongiform degeneration of the brain. Currently, there is no treatment for the disease and its natural course in children is irreversible brain damage and death within the first decade of life. 25, 26 An rAAV2-ASPA vector was recently used in a phase I clinical trial to monitor safety profile and immune responses to the rAAV vector in Canavan disease patients. 27 The trial consisted of 10 subjects that received intracranial infusions via six burr holes. Subjects were treated in two cohorts, with doses of 8 Â 10 11 and 1 Â 10 12 vg per patient. Although rAAV2 vector administration to the CNS appeared to be well tolerated, the study found a low-level immune response to AAV2 in 3 out of 10 subjects as determined by an increase in serum AAV2-neutralizing antibodies. Interestingly, examination of cerebrospinal fluid indicated a complete absence of neutralizing antibodies with no overt signs of brain inflammation. 27 Expansion into phase II/III studies and long-term monitoring will be necessary to determine the efficacy of this treatment.
The clinical utility of AAV vectors in the CNS to treat other neurological diseases has been widely investigated in a variety of animal models. This has certainly been the case for Parkinson's disease where an extensive use of rodent models has provided proof-of-principle experiments on the utility of AAV as a gene transfer tool. Although the clinical etiology of Parkinson's disease is still unknown, it is characterized by a specific degeneration of dopamine neurons in the substantia nigra, which project into the striatum resulting in rigidity and tremor. 28 Certain neurotrophic growth factors such as glial cell-derived neurotrophic factor and its naturally occurring functional analog neurturin (NTN) have been found to augment the function and protect the degeneration of dopaminergic neurons. To this effect, Ceregene recently conducted a phase I trial with an rAAV2-NTN vector also known as CERE-120. This study investigated the safety and tolerability of CERE-120 administration to the nigrostriatal system of 12 Parkinson's disease patients. This trial began in June 2005 and was completed in March 2006, thus patient safety assessment ranges from 9 to 12 months for the low-dose cohort and 4-8 months for the high-dose cohort. No adverse events related to CERE-120 have been reported to date. It has been reported by Ceregene that all subjects exhibited improvement in their 'Unified Parkinson's Disease Rating Scale' scores and had no signs of clinically significant changes on neuropsychiatric or physical and neurological examinations. With the conclusion of the phase I trial, Ceregene is currently recruiting patients for a phase II, double-blinded sham-controlled trial, to assess the efficacy of CERE-120 in patients with moderate-to-advanced Parkinson's disease.
Originally, the employment of AAV vectors for the treatment of Parkinson's disease involved prevention of dopaminergic neuron loss with neurotrophic factors and the expression of dopamine synthetic enzymes. 29, 30 Although these studies validated the safety and potential efficacy of AAV delivery to the brain, the potentially dangerous clinical strategy of long-term growth factor expression in humans is still a concern. An alternative therapeutic option for Parkinson's focused on subthalamic nucleus infusions with AAV vectors expressing the two isoforms of the enzyme glutamic acid decarboxylase (GAD 65 and GAD 67). These enzymes catalyze the synthesis of g-aminobutyric acid, the major inhibitory neurotransmitter in the brain. In patients with Parkinson's disease, activity of the subthalamic nucleus is increased mainly because of reduced g-aminobutyric acidergic input from the globus pallidus. 31, 32 This therapeutic strategy was employed in a phase I clinical trial on 12 patients with idiopathic Parkinson's disease undergoing surgery for the implantation of deep-brain stimulation electrodes. Patients were randomized into three groups receiving either low, medium or high doses of rAAV2-GAD. This open label, safety and tolerability trial of unilateral subthalamic nucleus injection had no adverse events related to the gene therapy. In addition, significant improvements in motor (Unified Parkinson's Disease Rating Scale) scores were seen on the side of the body collateral to surgery for 3 months to 1 year after subthalamic nucleus injection. In addition, positron emission tomography scans revealed a substantial reduction in thalamic metabolism restricted to the treated hemisphere. 33, 34 Other active rAAV therapeutic approaches to Parkinson's disease include the delivery of the normal human aromatic L-amino acid decarboxylase (AADC) gene into the striatum (Table 1 ). This approach is aimed at increasing the conversion of the commonly prescribed biosynthetic dopamine precursor (Levodopa) into dopamine by the AADC enzyme. As the levels of this enzyme decline with disease progression, larger doses of Levodopa are required for a clinical response; thus increasing AADC levels should enhance the effectiveness of the administered Levodopa. Pre-clinical studies in primates established a relationship between vector dose and L-Dopa responsiveness with a sharp improvement at the higher rAAVhAADC dose. 35 Additional studies in a primate Parkinson's disease model resulted in long-term improvement in clinical ratings and lower L-Dopa requirements; this study also showed an impressive transgene expression 6 years post-rAAVhAADC delivery. 36 This vector is currently undergoing phase I open-label safety studies.
Another area of CNS disease with AAV clinical trials is Alzheimer's disease. This neurodegenerative disorder is of unknown etiology but is characterized by the accumulation of amyloid plaques and neurofibrillary tangles throughout the brain, leading to a progressive loss of memory, judgment and language skills. Gene therapy for this disease has mainly focused on the secretion of b-nerve growth factor (NGF) to protect and reverse specific neuronal populations from degenerating with age and increasing the survival of cholinergic Clinical gene therapy using rAAV vectors C Mueller and TR Flotte neurons. AAV transfer with NGF has been documented to have improvements on the cholinergic function of neurons and memory. 37 Ceregene recently sponsored a phase I/II dose escalation trials with an rAAV2-NGF vector. Although information on these trials is hard to come by, according to their website 'Ceregene has completed an initial phase I clinical trialy and is planning a multi-center, controlled phase II trial.' Yet another currently active phase I clinical trial for CNS gene therapy is for late-infantile neuronal ceroid lipofuscinoses disease. This is another fatal pediatric neurodegenerative lysosomal storage disorder, also known as Batten disease, and is caused by the deficiency of a tripeptidyl peptidase. This enzyme is encoded by the CLN2 gene, and currently rAAV2-CLN2 augmentation therapy is being tested for safety of direct intracranial administration in individuals, with late-infantile neuronal ceroid lipofuscinoses and its efficacy in slowing down or halting disease progression. 38 
Anti-inflammatory gene therapy
Adeno-associated virus vectors have also been recently tested in vitro as gene delivery tools for synoviocytes and primary chondrocytes. 39 Furthermore, their gene transfer directly into joints has been demonstrated in rodent models of arthritis, specifically where the expression of a tumor necrosis factor-a (TNF-a) inhibitor was able to suppress arthritis in a streptococcus cell wall-induced arthritis rat model. This same anti-TNF-a therapy has been the focus of phase I/II trial sponsored by Targeted Genetics. The company initiated trials on their vector termed 'tgAAC94', which expresses an immunoglobulin Fc fragment fused to a soluble receptor for TNF-a. The phase I studies completed in 2005, evaluated the safety of intra-articular injection of tgAAC94 in subjects without concomitant systemic TNF-a antagonist therapy. From the 11 patients that received two escalating doses of tgAAC94, it was determined that 1 Â 10 11 DNAseresistant particles were well tolerated and no drugrelated serious adverse events were reported. This was followed by a phase I/II double-blinded, placebocontrolled trial with enrollment of 127 subjects to evaluate tgAAC94 at three doses in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis that may be receiving but not responding to anti-TNF-a therapy concomitantly. Although the trial is still ongoing, interim data from patients receiving 1 Â 10 11 DNAse-resistant particles showed a trend toward sustained improvement in tenderness and swelling for at least 12 weeks in treated joints as compared to placebo. Unfortunately, one of the subjects in the higher dose group had a fatal adverse event, leading to a temporary hold by the Food and Drug Administration on the trial. A review of the available data indicated that tgAAC94 did not contribute to the patient's death. The patient died from an opportunistic disseminated histoplasmosis infection with subsequent bleeding complication and multi-organ failure. Given the nature of this adverse event it seems very likely to have been related to suppression of innate immunity, which is the mechanism of action of several of the agents being used concomitantly to treat the arthritis in this patient, including adalimumab, methotrexate and prednisone. Thus, it seems very unlikely to have been vector related and certainly not generalizable as a whole to other rAAV vectors. The Food and Drug Administration has since lifted the hold on the phase I/II trial and additional data for subjects on the higher dose group are expected with the completion of the trial.
Progression from rAAV2 to rAAV1 clinical trials
The ability to cross-package or 'pseudotype' rAAV vectors into capsids from other serotypes has further broadened the potential utility of rAAV-based gene therapy. Early studies by a number of investigators have demonstrated that other rAAV serotypes may show greater efficiency for gene transfer in certain tissues as compared with the original rAAV2 vectors. In particular, it has been demonstrated that in mice, rAAV1 has higher efficiency for delivery to muscle; rAAV1, rAAV5 and rAAV6 for delivery to lung; and rAAV8 for delivery to liver. On the basis of these findings, a number of rAAV clinical programs that have been focused on muscle-directed gene transfer have moved to clinical trials of rAAV1 delivery.
rAAV1 gene therapy for a-1 antitrypsin
Gene augmentation for a-1 antitrypsin (AAT) deficiencyrelated lung disease could theoretically be accomplished by delivery to any of a variety of different cell types within the body, as the therapeutic effect of AAT in this context simply depends on restoration of plasma levels above a threshold value of 11 mM, regardless of the site of production. Early studies of IM injection of rAAV2-AAT vectors progressed in a manner similar to the IMdirected gene therapy program for hemophilia B with rAAV2-Factor IX vectors described above. [40] [41] [42] On the basis of positive proof-of-concept data in C57Bl6 and severe combined immunodeficient mice, and safety data in mice, rabbits and baboons, a phase I clinical trial of IM rAAV2-AAT was performed in 12 AAT-deficient adults. The dosages of vector in that trial ranged from approximately 2 Â 10 12 vg particles to nearly 7 Â 10 13 vg, with the maximal dose then being near 1 Â 10 12 vg kg
À1
for an average adult. Within this dose range, rAAV2-AAT IM delivery was quite safe. Humoral immune responses were raised to rAAV2 capsid, but antigen-specific lymphocyte proliferation responses (used as a surrogate for cell-mediated responses in this study) were not elicited. 43 Currently, a critical proof-concept and safety study is also being generated with the same AAT transgene cassette pseudotyped into AAV1 vectors, which according to some studies mediates 500-fold greater gene transfer efficiency. 44 This phase I clinical trial with IM administration of the rAAV1-AAT vector in a-1-deficient patients is currently being performed with doses of 6.9 Â 10 12 , 2.1 Â 10 13 and 6.0 Â 10 13 vg to three subjects in three cohorts respectively. Eight of the subjects have been dosed with no vector-related serious adverse events reported. The similar structure of the rAAV1-AAT and rAAV2-AAT clinical trials will allow for retrospective comparison of the dose-ranging data and allows one to determine whether the potency advantage predicted by the mouse studies will hold true in humans. It is hoped that the combined data from these two studies will provide important dose-ranging information for all human uses of rAAV vectors by the IM route. Celladon Corp. in a joint venture with Targeted Genetics has also developed plans for a clinical trial with AAV1. They are targeting heart-failure patients, with an rAAV1 vector expressing the Serca2a protein, which is a key regulatory protein for heart muscle contraction and relaxation involved in the reloading of sarcoplasmic reticulum with Ca
2+
. This protein has been found to be at low levels in heart failure and has been correlated with the reduced ability of the heart to pump blood. The phase I trial will focus on patients with nonischemic class III/IV heart failure that have progressive heart disease despite treatment with heart failure medications and devices. Currently, there is no information on the ongoing study.
The future of rAAV-based gene therapy
One of the most remarkable developments in the rAAV vector field has been the discovery of another 120 capsid isolates and genomic variants of AAV in natural populations of humans and nonhuman primates. This discovery, coupled with the pseudotyping technology described above, could allow for a dramatic expansion of the repertoire of clinical gene therapy with rAAV vectors. Already, it has become clear that certain tissues, such as cardiac muscle, may be matched with newer serotypes, such as rAAV9 to create important potential therapeutic avenues. Although each of these capsids may have its own distinctive profile of dose-related issues, it seems likely that most or all will retain the hallmark propensity of AAV for safe long-term persistence.
Countering this very promising trend in the field is the increasing awareness of the potential for cell-mediated immune responses to AAV capsid proteins to play some role in limiting the duration of rAAV-mediated effects. This phenomenon has still not been fully studied. As rAAV vectors do not express the capsid genes, the concept that transduced cells would be eliminated by effector T cells directed at capsid epitopes would suggest a fairly long-term display of those epitopes on the surface of transduced cells. This phenomenon could clearly differ in its intensity depending on the specific cell type involved and the vector dose.
Taken together, these observations strongly suggest that ongoing research is warranted. Basic studies on mechanisms of vector transduction, vector immunology and interactions with particular disease states must be furthered if the true clinical potential of rAAV is to become better known. The potential for combination of rAAV-mediated gene transfer with other novel therapeutic modalities, such as RNAi or stem cell therapy, warrants further study as well. If the key elements of the limiting processes can be clearly defined, the lessons learned could lead to major benefits in the long term.
Conclusions
The development of AAV vectors for gene therapy so far has an excellent safety record with data accumulated from thousands of animal studies and hundreds of human patients. Although clinical experience with AAV is still in its infancy, some of the problems in the translation of preclinical results to human patients stem from the previously undetected immunogenicity of the AAV capsid. A more thorough evaluation of innate and acquired immune responses to the available serotypes is required. Strategies to modulate and transiently suppress the host immune responses need to be further investigated to determine if they will eventually be clinically applicable. However, it appears from the clinical trials in Parkinson's disease that small doses of AAV vector in immunoprivileged sites such as the brain and the eye for RPE65 may tolerate AAV delivery without further immune modulation.
